Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about cross-border ordering, and it is deliberately narrow — everything I am not confident about is marked as such.
The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines, and whether the shipment looks commercial. Personal-import allowances exist in some jurisdictions and not in others, and where they exist they are usually conditional on a prescription and a quantity limit. The failure mode is normally a seizure notice rather than anything worse, and a reshipment policy is the thing worth confirming before ordering rather than after.
Cold chain is the underrated risk on long routes. A shipment held at a border for a week has had a temperature excursion whether or not it arrives.
The question I want answered is which of the variables in a cross-border order actually determine the outcome, and which are superstition. Not looking for reassurance. Looking for the part I have got wrong.
Dr.LipidDallas said:The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…
Agreed, and hsCRP is worth reading alongside them. The inflammatory-marker fall is often the most striking change on a panel and it is consistent with the cardiovascular outcome data.
Dr.LipidDallas said:The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…
This is where I part company with the consensus forming above. Import rules are jurisdiction-specific and this board keeps giving US-shaped answers to non-US questions. What is a personal-import allowance in one country is a controlled-import offence in another.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsShort answer first, then the reasoning. ApoB is the more informative number and it is cheap. LDL-C estimates cholesterol mass in atherogenic particles; ApoB counts the particles, and it is particle count that tracks risk — which is why the two can disagree and why the disagreement is the clinically interesting case. Triglycerides fall substantially with weight loss and improved insulin sensitivity, HDL moves modestly, and LDL-C often barely moves at all, which surprises people who expected everything to improve together.